Vibostolimab is under clinical development by Merck & Co and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Vibostolimab’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 20 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vibostolimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Vibostolimab (MK-7684) is under development for the treatment of solid tumors including melanoma, non-small cell lung cancer and adenocarcinoma of the gastroesophageal junction. The drug candidate is administered by intravenous route. It acts by targeting TIGIT protein.
Merck & Co overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Quick View Vibostolimab LOA Data
|Highest Development Stage|